Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li X, Liu Y, Yao H, Wang M, Gao L, Lou J, Mao J, Wu W, Zhou Y, Tang Y, Yan W, Hu Y, Ding C, Chen S, Niu J, Ding Y. Li X, et al. Among authors: lou j. Antimicrob Agents Chemother. 2022 May 17;66(5):e0009422. doi: 10.1128/aac.00094-22. Epub 2022 Apr 11. Antimicrob Agents Chemother. 2022. PMID: 35404074 Free PMC article. Clinical Trial.
Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach.
Ding YH, Liu B, Lou JF, Sun JX, Wu M, Zhu XX, Chen GL, Zhang H, Li XJ, Chen H, Liu CJ, Shen ZW, Li CY. Ding YH, et al. Among authors: lou jf. Clin Pharmacol Drug Dev. 2019 Aug;8(6):713-720. doi: 10.1002/cpdd.624. Epub 2018 Oct 16. Clin Pharmacol Drug Dev. 2019. PMID: 30325583 Clinical Trial.
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects.
Li X, Li Q, Ji T, Zhang H, Liu J, Wu M, Chen H, Lou J, Liu C, Xu Z, Ding Y. Li X, et al. Among authors: lou j. Expert Opin Investig Drugs. 2022 Jul;31(7):729-736. doi: 10.1080/13543784.2022.2078192. Epub 2022 May 18. Expert Opin Investig Drugs. 2022. PMID: 35574691 Clinical Trial.
First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects.
Zhang H, Gao L, Lou J, Wu M, Chen H, Yang L, Liu J, Zhu X, Li X, Li C, Wang M, Liu C, Guo W, Wang Y, Gao Z, Han L, Wang D, Jin W, Ding Y. Zhang H, et al. Among authors: lou j. Front Pharmacol. 2022 May 19;13:873588. doi: 10.3389/fphar.2022.873588. eCollection 2022. Front Pharmacol. 2022. PMID: 35662718 Free PMC article.
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
Li X, Liu Y, Wang M, Gao L, Liu J, Zhang H, Wu M, Chen H, Lou J, Wang J, Chen J, Geng G, Ma Z, Ding Y. Li X, et al. Among authors: lou j. Lancet Infect Dis. 2024 Jun;24(6):650-664. doi: 10.1016/S1473-3099(24)00003-3. Epub 2024 Feb 12. Lancet Infect Dis. 2024. PMID: 38359854 Clinical Trial.
2,681 results